Humacyte (HUMA) H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025 summary

Product innovation and clinical data

• SYMVESS, an engineered human tissue for vascular repair, was FDA approved in December and launched in February, offering off-the-shelf availability and an 18-month shelf life.

• Clinical studies showed SYMVESS had better patency, lower infection, and lower amputation rates compared to plastic grafts, with supporting data from both civilian and wartime settings.

• The product is being evaluated for additional indications, including peripheral artery disease and CABG surgery.

Market opportunity and commercial strategy

• The target market for vascular trauma is about 26,000 cases annually, concentrated in 200 level one trauma centers, allowing for a focused sales approach.

• Early sales reached $500,000 in the first month, with active Value Analysis Committee (VAC) submissions in over 40 trauma centers, representing nearly a quarter of the target centers.

• Most sales are expected in the second half of the year due to the lengthy VAC process.

Reimbursement and economic impact

• Hospitals purchase SYMVESS directly and are incentivized by lower complication rates, which reduce overall care costs.

• A new technology add-on payment (NTAP) decision from Medicare is expected in August, potentially reimbursing up to 65% of the product's list price and accelerating adoption.

• Budget impact models show SYMVESS is less expensive for hospitals compared to synthetic grafts, even without NTAP.